PLK3 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL376059	0.67	17/20
SCHEMBL376242	0.53	17/20
SCHEMBL376289	0.77	16/20
SCHEMBL376022	0.69	16/20
SCHEMBL376162	0.65	16/20
SCHEMBL376761	0.61	16/20
SCHEMBL376762	0.61	16/20
SCHEMBL376029	0.54	16/20
SCHEMBL376244	0.54	16/20
SCHEMBL375822	0.85	15/20
SCHEMBL376101	0.73	15/20
SCHEMBL376206	0.72	15/20
SCHEMBL376207	0.72	15/20
SCHEMBL376104	0.71	15/20
SCHEMBL375837	0.71	15/20
SCHEMBL376041	0.67	15/20
SCHEMBL376020	0.67	15/20
SCHEMBL376181	0.67	15/20
SCHEMBL376129	0.65	15/20
SCHEMBL376078	0.64	15/20

Clinical trials — most relevant to PLK3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Cardiac REperfusion With Intralipid® at Reperfusion	PHASE2/PHASE3	UNKNOWN
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression	PHASE2	COMPLETED
LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer	PHASE2	COMPLETED
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor	PHASE2	ACTIVE_NOT_RECRUITING
CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer	PHASE2	ACTIVE_NOT_RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Biological Effects of Quercetin in COPD Phase II	PHASE2	UNKNOWN
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors	PHASE1	COMPLETED
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	PHASE1	COMPLETED
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Study of PLX2853 in Advanced Malignancies.	PHASE1	COMPLETED
AZD1775 for Advanced Solid Tumors	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Identification of Disease Specific Pathways and Modifiers in Phospholamban R14del Cardiomyopathy	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Phosphoproteomic Patterns as a Novel Biomarker for Aurora and Polo-like Kinase Inhibitors in Non-Small Cell Lung Cancer	nan	COMPLETED
Poor Sleep and Inflammation in HIV-Infected Adults	nan	COMPLETED
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Vulvodynia: Identification of Potential Relevant Biomarkers	nan	COMPLETED
Protein Intake and Step Reduction in Older Adults	nan	COMPLETED
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies	nan	ENROLLING_BY_INVITATION
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer	nan	UNKNOWN
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PLK3 binder may also engage these)

Protein	Name	Similarity
Q9R011	—	1.000	Q9R011 →
Q60806	—	1.000	Q60806 →
MAP3K6	Mitogen-activated protein kinase kinase kinase 6	0.986	landscape →
Q9WTR2	—	0.982	Q9WTR2 →
FGFR4	Fibroblast growth factor receptor 4	0.982	landscape →
Q99ML2	—	0.982	Q99ML2 →
Q8K045	—	0.982	Q8K045 →
P70218	—	0.981	P70218 →
RNF31	E3 ubiquitin-protein ligase RNF31	0.980	landscape →
Q9Y613	—	0.980	Q9Y613 →
GRB7	Growth factor receptor-bound protein 7	0.980	landscape →
TNK1	Non-receptor tyrosine-protein kinase TNK1	0.979	landscape →
Q80XI6	—	0.979	Q80XI6 →
O76050	—	0.978	O76050 →
B5DFA1	—	0.978	B5DFA1 →
Q8BXP5	—	0.978	Q8BXP5 →
P70268	—	0.978	P70268 →
Q9BYX2	—	0.978	Q9BYX2 →
PINK1	Serine/threonine-protein kinase PINK1, mitochondrial	0.978	landscape →
PKN3	Serine/threonine-protein kinase N3	0.978	landscape →
Q3T033	—	0.977	Q3T033 →
P54265	—	0.977	P54265 →
Q66HA1	—	0.977	Q66HA1 →
B5KFD7	—	0.977	B5KFD7 →
P55146	—	0.977	P55146 →
ERN2	Serine/threonine-protein kinase/endoribonuclease IRE2	0.977	landscape →
Q9BYB0	—	0.977	Q9BYB0 →
DMPK	Myotonin-protein kinase	0.977	landscape →
Q498D6	—	0.977	Q498D6 →
Q99MQ3	—	0.977	Q99MQ3 →